newsfilter
← Latest News
ACCESS Newswire·

Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases

Latest Testing Eliminates Interleukin-2 From Cerebral Spinal Fluid JACKSON CENTER, PA / ACCESSWIRE / December 20, 2021 / Halberd Corporation (OTC:HALB) has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CS